Representative before the EPO

Employment test 51 - 200 employees
Company dna d young and co llp
operating since 1891
Headquarter in London and 2 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

We have observed 34 EP applications Neil Jacob Nachshen has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after November 27, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12757133

COMBINATION OF ANTI-CLUSTERIN OLIGONUCLEOTIDE WITH HSP90 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER

IPC classification:
A61K 31/7088, A61K 31/4162, A61P 35/00
Applicant:
The University of British Columbia
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12757052

COMBINATION OF ANTI-CLUSTERIN OLIGONUCLEOTIDE WITH ANDROGEN RECEPTOR ANTAGONIST FOR THE TREATMENT OF PROSTATE CANCER

IPC classification:
A61K 31/7088, A61K 31/4166, A61P 35/00, A61P 5/28
Applicant:
The University of British Columbia
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13176166

Rasagiline for parkinson's disease modification

IPC classification:
A61P 25/16, A61K 31/135, A01N 33/02
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12817089

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE

IPC classification:
A61K 31/47, A01N 43/42
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12755869

POLYMORPHIC FORM OF PRIDOPIDINE HYDROCHLORIDE

IPC classification:
A61K 31/445, C07D 211/24, A61P 25/28
Applicant:
Teva Pharmaceuticals International GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
The patent has been granted
EP12835589

ANTIBODIES AGAINST TL1A AND USES THEREOF

IPC classification:
A61K 39/395, C07K 16/24, A61P 29/00
Applicant:
Teva Pharmaceuticals Australia Pty Ltd
Agent:
Multiple attorneys, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13187258

Stable laquinimod preparations

IPC classification:
A61K 31/47, A61K 31/438, C07D 471/10, C07D 209/42, C07D 209/34
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP12840164

ANTIBODIES TO CD1d

IPC classification:
A61K 39/395, C12N 15/13, C12N 5/10, C07K 16/28, A61P 43/00, A61P 17/06, A61P 11/06, A61P 9/10, A61P 1/16
Applicant:
Teva Pharmaceuticals Australia Pty Ltd
Agent:
Multiple attorneys, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12840243

SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT CLINICAL RESPONSE FOR GLATIRAMER ACETATE

IPC classification:
A01N 37/12, C12Q 1/68
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12840761

R(+)-N-METHYL-PROPARGYL-AMINOINDAN

IPC classification:
A61K 31/135
Applicant:
Teva Pharmaceutical Industries Ltd.
Applicant:
Teva Pharmaceuticals USA Inc
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12840715

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FINGOLIMOD

IPC classification:
A61K 31/47, A61K 31/135
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12775541

NOVEL PEPTIDES

IPC classification:
C07K 14/435
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13153698

Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof

IPC classification:
A61K 31/4704, C07D 215/56, C07D 215/54, C07D 215/22
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13159275

Taxoid - Purification of Liquid Excipients

IPC classification:
A61K 47/10, A61K 9/00
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP12855452

THE HYDROBROMIDE SALT OF PRIDOPIDINE

IPC classification:
A61K 31/4453, C07D 211/00, A61P 25/28
Applicant:
Teva Pharmaceuticals International GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12805898

TOFACITINIB SALTS

IPC classification:
A61K 31/519, C07D 487/04, A61P 35/00
Applicant:
Ratiopharm GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP12840538

RASAGILINE CITRAMIDE

IPC classification:
A61K 31/16
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13744015

USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY

IPC classification:
A61K 31/47, A01N 43/42
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13749429

N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINE CARBOXAMIDE, PREPARATION AND USES THEREOF

IPC classification:
A61K 31/4704, C07D 215/56
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP14181161

BChE albumin fusions for the treatment of cocaine abuse

IPC classification:
A61K 38/46, A61K 38/38, A61K 38/16, A61P 25/30
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14186019

Polymorphic form of imatinib mesylate and process for its preparation

IPC classification:
A61K 31/506, C07D 401/04, A61P 35/00
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13768294

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND DIMETHYL FUMARATE

IPC classification:
A61K 31/4704
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP12817547

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND INTERFERON-BETA

IPC classification:
A61K 38/21, A61K 31/4704, A61K 31/47, A61P 25/00
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13784231

USE OF HIGH DOSE LAQUINIMOD FOR TREATING MULTIPLE SCLEROSIS

IPC classification:
A61K 31/47
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13772325

PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY

IPC classification:
A61P 25/14
Applicant:
Teva Pharmaceuticals International GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION REQUESTED
EP13791341

METHOD FOR TREATING NON-SMALL CELL LUNG CANCER

IPC classification:
A61K 31/7105
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14185362

Tigecycline crystalline forms and processes for preparation thereof

IPC classification:
C07C 237/26, C07C 231/24
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP13816075

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FAMPRIDINE

IPC classification:
A01N 45/00, A01N 43/42, A61P 25/02
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13816725

LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT

IPC classification:
A61K 31/47
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13740041

ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB

IPC classification:
A61K 31/519, A61K 31/4045, A61K 9/48, A61K 9/20
Applicant:
Ratiopharm GmbH
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13829849

LAQUINIMOD FOR TREATMENT OF CANNABINOID RECEPTOR TYPE 1 (CB1) MEDIATED DISORDERS

IPC classification:
A61K 31/4704, A61P 25/02
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13752800

PHARMACEUTICAL COMPOSITIONS OF MEMANTINE

IPC classification:
A61K 31/13, A61K 9/50, A61K 9/48, A61K 9/20, A61K 9/16
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
PATENT GRANTED
EP13829655

PARENTERAL FORMULATION OF RASAGILINE

IPC classification:
A61K 31/136, A61K 31/135, A61P 25/00
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13840841

LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS

IPC classification:
A61P 25/28, A61P 25/18, A61P 25/00
Applicant:
Teva Pharmaceutical Industries Ltd.
Agent:
Neil Jacob Nachshen, D Young & Co LLP
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature